Use of biomarkers in ALS drug development and clinical trials

Abstract

The past decade has seen a dramatic increase in the discovery of candidate biomarkers for ALS. These biomarkers typically can either differentiate ALS from control subjects or predict disease course (slow versus fast progression). At the same time, late-stage clinical trials for ALS have failed to generate improved drug treatments for ALS patients. Incorporation of biomarkers into the ALS drug development pipeline and the use of biologic and/or imaging biomarkers in early- and late-stage ALS clinical trials have been absent and only recently pursued in early-phase clinical trials. Further clinical research studies are needed to validate biomarkers for disease progression and develop biomarkers that can help determine that a drug has reached its target within the central nervous system. In this review we summarize recent progress in biomarkers across ALS model systems and patient population, and highlight continued research directions for biomarkers that stratify the patient population to enrich for patients that may best respond to a drug candidate, monitor disease progression and track drug responses in clinical trials. It is crucial that we further develop and validate ALS biomarkers and incorporate these biomarkers into the ALS drug development process. This article is part of a Special Issue entitled ALS complex pathogenesis.

Keywords: ALS; Biomarkers; Clinical trial; Pharmacodynamic biomarker; Prognostic biomarker.

Figure 1

Use of biomarkers in ALS drug development and clinical trials. Biomarker discovery and validation efforts incorporate various model systems and patient population, using –omics based technologies and imaging. These biomarkers are used to identify pathways to target for drug development, selection of patients for clinical trials, target engagement of the drug and determining efficacy within the patients.